Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:05 2024-05-16 pm EDT 		5-day change 1st Jan Change
771.6 USD -1.96% Intraday chart for Eli Lilly and Company +0.00% +32.36%
May. 16 Health Care Flat as Momentum Wanes -- Health Care Roundup DJ
May. 16 Eli Lilly: research collaboration with Totus Medicines CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 694,321 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 714,302 709,606 703,345
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 57.7 x 41.5 x 32.2 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.67% 0.78% 0.85%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 16.1 x 13.2 x 11.2 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 16.6 x 13.5 x 11.3 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 44.1 x 33 x 25.6 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 78.9 x 51 x 37.9 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 1.27% 1.96% 2.64%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 39 x 24 x 16 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,405 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 771.1 771.1 771.1
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 43,027 52,496 62,055
EBITDA 1 7,551 8,589 10,005 9,472 8,584 16,205 21,530 27,455
EBIT 1 6,079 7,265 8,457 7,950 7,057 14,701 19,893 25,492
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 34.17% 37.89% 41.08%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 13,737 18,597 22,671
Net income 1 8,318 6,194 5,582 6,245 5,240 11,932 16,553 21,400
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 27.73% 31.53% 34.49%
EPS 2 8.890 6.790 6.120 6.900 5.800 13.37 18.58 23.94
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 9,050 13,912 18,540
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 21.03% 26.5% 29.88%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 55.85% 64.62% 67.53%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 75.85% 84.04% 86.64%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.199 5.993 6.587
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,768 10,024 11,347 12,824 10,745 11,515
EBITDA 1 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 3,049 3,747 4,838 5,994 - -
EBIT 1 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,648 3,080 3,976 4,816 - -
Operating Margin 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 30.2% 30.72% 35.04% 37.55% - -
Earnings before Tax (EBT) 1 - - - - - - 2,089 427.2 2,509 2,536 3,000 3,878 4,496 - -
Net income 1 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,243 2,477 3,249 4,025 - -
Net margin 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 25.58% 24.71% 28.63% 31.39% - -
EPS 2 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.480 2.774 3.604 4.460 - -
Dividend per Share 2 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.300 1.300 1.300 1.299 - -
Announcement Date 2/3/22 4/28/22 8/4/22 11/1/22 2/2/23 4/27/23 8/8/23 11/2/23 2/6/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 19,982 15,286 9,024
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.233 x 0.71 x 0.3287 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 9,050 13,912 18,540
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 82.7% 73.7% 65.6%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 17.6% 21.3% 24.7%
Assets 1 62,143 42,961 35,816 42,708 56,748 67,726 77,640 86,770
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 19.80 32.20 48.20
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.40 20.00 25.20
Capex 1 1,034 1,388 1,310 1,854 3,448 3,668 2,964 3,083
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 8.52% 5.65% 4.97%
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.1 USD
Average target price
850.4 USD
Spread / Average Target
+10.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.77% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.77% 239B
NOVARTIS AG Stock Novartis AG
+9.13% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-3.97% 209B
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Financials Eli Lilly and Company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW